Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04486833
Title TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone (Acclaim-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.

lung non-small cell carcinoma


Osimertinib + Quaratusugene Ozeplasmid


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.